The disclosure provides among others a combination of a vaccine and a CD94/NKG2A and/or a CD94/NKG2B binding antibody for use in the treatment of a subject in need thereof, wherein said vaccine comprises an immunogen for eliciting an immune response against an antigen or a nucleic acid molecule encoding said immunogen.